Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- NYU researcher awarded $1.7 million NIH grant to optimize cancer treatmenton October 29, 2019 at 5:24 am
The five-year, $1.7 million grant will support Chen's lab's efforts to devise engineering-based methods for understanding and improving the efficacy of immunotherapy treatment for cancer. Chen, who ...
- AstraZeneca reports promising lung cancer results from Phase III immunotherapy drug trialon October 29, 2019 at 5:17 am
A British drugmaker’s program to develop an immunotherapy combination for a type lung cancer that could compete with one of the more established drugs for the disease has partially paid off.
- Sales of Merck's Cancer Treatment Keytruda Soar in 3Qon October 29, 2019 at 4:26 am
Revenue jumped 15% to of $12.4 billion. Sales of Merck's cancer immunotherapy drug Keytruda soared to $3.1 billion in the quarter. Merck expects full-year earnings in the range of $5.12 to $5.17 per ...
- If we build it they will come: targeting the immune response to breast canceron October 29, 2019 at 3:32 am
The goal of these approaches is to alter the TME, thereby making breast tumors more responsive to immunotherapy. In this review, we summarize key developments in our understanding of antitumor ...
- AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck…on October 29, 2019 at 3:27 am
Pembrolizumab, marketed by Merck (MRK) as Keytruda, is a next-gen cancer therapy used in immunotherapy against a variety of advanced cancers. A humanized antibody which was initially approved by FDA ...
- Applied BioMath, LLC Announces Participation at The Society for Immunotherapy of Cancer (SITC)on October 28, 2019 at 1:48 pm
CONCORD, Mass., Oct. 28, 2019 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to ...
- The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapyon October 28, 2019 at 9:15 am
Second, failure to trigger NMD is a cause of ineffective gene inactivation by CRISPR–Cas9 gene editing. Finally, NMD is a determinant of the efficacy of cancer immunotherapy, with only frameshifted ...
- Catalytic immunotherapy for cancer: Nanoparticles act as artificial enzymeson October 25, 2019 at 6:33 am
Despite modern cancer treatments, metastases and relapses remain a major problem ... So-called nanoenzymes are hot candidates for treatments called catalytic immunotherapy. These nanoparticles have ...
- Cancer treatment: A researcher makes breakthrough immunotherapy discoveryon October 25, 2019 at 12:34 am
To date, the effectiveness of the new form of immunotherapy against leukemia and some skin cancers has been demonstrated in animals. The next stage will be clinical trials with human subjects. "This ...
- Cancer Immunotherapy: Getting Better with a Little Help from Helper T Cellson October 24, 2019 at 3:53 am
“[Our] study reveals for the first time that helper T cells are essential in cancer immunotherapy,” said Robert D. Schreiber, PhD, a professor of microbiology and the Andrew M. and Jane M. Bursky ...
via Bing News